A. 25
Feedback Council for Scientific and Industrial Research (CSIR) has identified the top 25 drugs/drug candidates for repurposing as they can be quickly deployed for treatment. On of the top 25 drugs is Favipiravir. Favipiravir is a broad-spectrum inhibitor of viral RNA polymerase and has emerged as one of the most promising drugs. Favipiravir was developed by Fujifilm Toyama Chemical Ltd. It is an approved treatment for common influenza and is marketed in Russia, China, and Japan